Showing 5781-5790 of 7317 results for "".
- FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinomahttps://practicaldermatology.com/news/fda-agrees-to-priority-review-of-cemiplimab-for-advanced-squamous-cell-carcinoma/2457785/The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC w
- New Phase 4 Data: Epiduo Forte Gel Decreased Acne Lesions, Reduced Risk of Scarshttps://practicaldermatology.com/news/new-phase-4-data-epiduo-forte-gel-decreased-acne-lesions-reduced-risk-of-scars/2457788/Results from OSCAR, a Phase 4, multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left half-face), revealed that Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% not only decreased acne lesions, as measured over a period of
- Acne Survey at Twins Convention Affirms Genetic Linkhttps://practicaldermatology.com/news/acne-survey-at-twins-convention-affirms-genetic-link/2457789/A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, OH, and published in the April issue of the Journal of Drugs in Dermatology, shows acne may be primarily caused by genetics.
- Parents Just Don't Understand Risks of Sun Exposure in Springhttps://practicaldermatology.com/news/parents-just-dont-understand-risks-of-sun-exposure-in-spring/2457791/Slightly more than 90 percent of parents underestimate the sun’s strength in spring and as a result, don’t adequately protect their children, according to a survey by parent magazine Kinderzeit.org. Specifically, 90.6 percent of parents polled tend to forget to apply sun
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- Saudi Arabia Welcomes Scalisi Skin Carehttps://practicaldermatology.com/news/saudi-arabia-welcomes-scalisi-skin-care/2457799/Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on QVC.com, Amazon.com, and
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20
- New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologieshttps://practicaldermatology.com/news/new-jama-dermatology-publication-features-aid-accelerator-fund-to-enable-progress-of-promisingearly-stage-scientific-technologies/2457810/A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development
- FDA Approves Sonoma Pharmaceuticals' Antimicrobial Post-Therapy Gelhttps://practicaldermatology.com/news/fda-approves-sonoma-pharmaceuticals-antimicrobial-post-therapy-gel/2457813/Sonoma Pharmaceuticals, Inc. has received a new 510(k) clearance from the FDA for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E